MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ANL

ANL

Adlai Nortye Ltd.

$9.5
-1.1
 (-10.38%)
Exchange:  NASDAQ
Market Cap:  504.26M
Shares Outstanding:  8.48M
Delayed data
Calculate ANL Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Yang Lu
Full Time Employees:  123
Address: 
Ugland House
Grand Cayman
KY1-1104
KY
Website:  https://www.adlainortye.com
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company’s pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company’s headquarters are situated in Grand Cayman, Cayman Islands.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue005,000
Gross Profit005,000
EBITDA-106,215-48,055-32,627
Operating Income-72,551-52,928-35,698
Net Income-109,228-51,869-35,528

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets130,18971,27034,433.146
Total Liabilities50,78645,78542,755.182
Total Stockholders Equity79,403.01525,485-8,322.035
Total Debt31,54827,22626,376.111
Cash and Cash Equivalents91,492.01860,90223,786.101

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-56,652-51,819-33,539.469
Capital Expenditure-200-170-187.491
Free Cash Flow-56,852-51,989-33,726.960
Net Income-104,871-51,869-35,621.962
Net Change in Cash48,734-30,590-37,115.731

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)1,266.667Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,266.667Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,266.667Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)253.333Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)253.333Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)253.333Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-9,219.306Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)-9,219.306Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)-9,219.306Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)1,223.416Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)1,223.416Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)1,223.416Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)-0.870Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)-0.870Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.870Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
106.16
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-3
?Enterprise Value
 (TTM)
: 
533.39M  ?EV/FCF
 (TTM)
: 
-15.81
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-414.01%  ?ROIC
 (TTM)
: 
-197.73%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
-3.17
?P/B
 (TTM)
: 
-12.81  ?Current Ratio
 (TTM)
: 
0.65

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ANL valuation

Is Adlai Nortye Ltd. (ANL) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Adlai Nortye Ltd. (ANL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ANL a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ANL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ANL’s P/E ratio?

You can see ANL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ANL?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ANL a good long-term investment?

Whether ANL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ANL

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-10.38
MARKETSnap

Trading Metrics:

Open: 10.58   Previous Close: 10.6
Day Low: 9.5   Day High: 11.35
Year Low: 0.88   Year High: 17.25
Price Avg 50: 12.15   Price Avg 200: 6.45
Volume: 138168   Average Volume: 349527

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
20-05-2026 13:01
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read